Apyx Medical (APYX) Short term Debt (2010 - 2023)

Apyx Medical's (APYX) quarterly Short term Debt came in at $8.9 million in Q2 2023, up 1.3% on a QoQ basis from $8.8 million in Q1 2023.

Apyx Medical (APYX) Short term Debt (2010 - 2023) Analysis & Trends

Apyx Medical (APYX) has 12 years of Short term Debt data on file, last reported at $8.9 million in Q2 2023.

Quarterly Short term Debt changed N/A year-over-year to $8.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $8.9 million (changed N/A YoY) and the FY2019 annual result came in at $140000.0, changed N/A from the prior year.
Short term Debt advanced to $8.9 million in Q2 2023, from $8.8 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $8.9 million in Q2 2023 to a low of $140000.0 in Q4 2019.
A 3-year average of $3.0 million and a median of $140000.0 in 2019 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.49 Bn	193.88 Bn	7.27 Bn
2	Stryker	127.80 Bn	124.32 Bn	4.50 Bn
3	Medtronic	118.98 Bn	109.76 Bn	6.41 Bn
4	Boston Scientific	73.58 Bn	73.04 Bn	3.85 Bn
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn
6	Dexcom	34.34 Bn	32.39 Bn	830.00 Mn
7	GE HealthCare Technologies	33.76 Bn	31.66 Bn	2.18 Bn
8	Koninklijke Philips	26.37 Bn	23.05 Bn	4.55 Bn
9	Steris	23.07 Bn	22.59 Bn	684.20 Mn
10	Apyx Medical	135.93 Mn	108.32 Mn	8.87 Mn

Download Data